Endpoints News
Summit withdraws $500M offering Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T W Thu F
11 June, 2026
The Endpoints 100: Despite all the turmoil, biotech is having a moment
A year ago, biotech was in its bleakest stretch in a decade. Now IPOs are rebounding and China deals are heating up. John Carroll and a panel of industry leaders dig into the latest Endpoints 100 results and uncover what’s next for the sector.
presented by McKesson
De­liv­er­ing ex­cel­lence, close to home: Build­ing the in­fra­struc­ture for mod­ern com­mu­ni­ty on­col­o­gy
top stories
1. Here are biopharma’s 10 highest-paid scientists and doctors for 2025 
2. Summit withdraws $500M offering, citing 'market conditions'
3. Kardigan's $320M IPO pitch: Three borrowed heart drugs, one proven cardio CEO
4.
news briefing
Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophy
5. Exclusive: Genentech lays off top scientist Vishva Dixit, closes infectious disease research unit in restructuring
6. Takeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3
7. Neion Bio lands $23M Series A to make proteins from chicken eggs
8. Now at FDA’s doorstep, Beren Therapeutics tacks on $300M in new financings
more stories
• 
Karen Weintraub
.

It’s not just CEOs who are well-paid in biopharma. As Andrew Dunn’s series on industry pay continues, he explores the packages provided to two handfuls of scientists and doctors.
.
Karen Weintraub
Deputy Editor, Endpoints News
1
by Andrew Dunn

Bio­phar­ma’s top sci­en­tists and doc­tors don’t make near­ly as much as CEOs, but some still took in eight-fig­ure pay pack­ages in 2025.

As part of...

Read the full story
2
by Max Gelman

The cur­rent biotech en­vi­ron­ment can ap­par­ent­ly sup­port an in­dus­try-record IPO and si­mul­ta­ne­ous­ly ham­per ef­forts to raise half a bil­lion dol­lars.

Sum­mit Ther­a­peu­tics ditched plans for...

Read the full story
3
by Kyle LaHucik

Para­bilis Med­i­ci­nes' record-break­ing IPOwill be a tough act to fol­low, but a drug de­vel­op­er with three late-stage car­dio med­i­cines is up for the chal­lenge...

Read the full story
News Briefing: Quick hits from the biopharma web
4
by ENDPOINTS

Plus, news about Imaavy. 

👂 Sen­so­ri­on se­lects one hear­ing loss pro­gram, ax­es an­oth­er: The biotech is end­ingthe de­vel­op­ment of SENS-501 for OTOF-re­lat­ed hear­ing loss...

Read the full story
5
by Andrew Dunn

Roche's Genen­tech un­der­went an­oth­er round of lay­offs this week in its ear­ly re­search and de­vel­op­ment group, End­points News has learned, which in­clud­ed shut­ter­ing two re­search...

Read the full story
6
by Max Gelman

Take­da’s $4 bil­lion bet on an oral plaque pso­ri­a­sis drug has paid off again, as the com­pa­ny re­port­ed the pill beat Bris­tol My­ers Squibb’s So­tyk­tu...